Octreotide scan [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.

====== Octreotide scan ======

An [[octreotide]] scan or octreoscan is a type of [[scintigraphy]] used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide, a drug similar to somatostatin, is radiolabeled with indium-111,[1] and is injected into a vein and travels through the bloodstream. The radioactive octreotide attaches to tumor cells that have receptors for somatostatin. A gamma camera detects the radioactive octreotide and makes pictures showing where the tumor cells are in the body.

Octreotide scanning is reported to have a sensitivity between 75% and 100% for detecting pancreatic neuroendocrine tumors.


=====Indications====

For [[acromegaly]]:  [[SPECT]] imaging 4 and 24 hours after injection with 6.5 [[mCi]] of [[indium-111]] OctreoScan, a [[somatostatin receptor]] imaging agent.
----

An octreotide scan may be used to locate suspected primary neuroendocrine tumours (NET) or for follow-up or staging after treatment.

====Procedure====
The 111In-pentetreotide radiopharmaceutical is prepared from a kit in a radiopharmacy. Pentetreotide is a DTPA conjugate of octreotide.

Approximately 200 megabecquerels of Indium-111 is injected intravenously. Imaging takes place 24 hours after injection, but may also be carried out at 4 and 48 hours.